Adial Pharmaceuticals appoints David Rubenstein as chief scientist
ADIL•Adial Pharmaceuticals appointed David Rubenstein as chief scientist to lead research and scientific strategy. He will oversee AT177 development for ulcerative colitis, with first-in-human trials expected in 2027.
1. Research leadership
Rubenstein previously served as Dermavant Sciences’ chief scientific officer, leading tapinarof development through commercialization. At Adial, he will oversee AT177 development for ulcerative colitis, with first-in-human trials expected in 2027.
